Business
Total Voting Rights Update
Total Voting Rights Update.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \n \n Shield Therapeutics plc\n \n \n (\"Shield\" or the \"Company\" or the \"Group\")\n \n \n \n \n \n \n Total Voting Rights Update\n \n \n \n \n \n \n \n London, UK, 28 February 2023: \n Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 585,669,777 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\n \n \n \n \n The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n Shield Therapeutics plc\n \n \n \n \n \n www.shieldtherapeutics.com\n \n \n \n \n \n \n Greg Madison, CEO\n \n \n +44 (0) 191 511 8500\n \n \n \n \n Hans-Peter Rudolf, CFO\n \n \n \n \n \n \n \n \n \n Nominated Adviser and Joint Broker\n \n \n \n \n \n \n \n \n \n Peel Hunt LLP\n \n \n \n \n \n \n \n \n James Steel/Oliver Duckworth\n \n \n +44 (0)20 7418 8900\n \n \n \n \n \n \n Joint Broker\n \n \n finnCap Ltd \n \n Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks \n \n \n \n \n \n +44 (0)20 7220 0500\n \n \n \n \n \n \n \n \n \n \n \n \n \n Financial PR & IR Advisor\n \n \n \n \n \n \n \n \n \n Walbrook PR\n \n \n \n \n \n \n \n \n \n Lianne Applegarth/Alice Woodings\n \n \n \n \n +44 (0)20 7933 8780 or \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Investor Contact (US Advisor)\n \n \n \n \n LifeSci Advisors, LLC\n \n \n \n John Mullaly\n \n \n \n \n \n +1 617 429 3548 or [email protected]\n \n \n \n \n \n \n About Accrufer®/Feraccru®\n \n Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to ...